WORK Medical Technology Group LTD Class A
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell WOK and other ETFs, options, and stocks.About WOK
WORK Medical Technology Group Ltd. engages in the development of health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets.
CEOShuang Wu
CEOShuang Wu
Employees238
Employees238
HeadquartersHangzhou, Zhejiang
HeadquartersHangzhou, Zhejiang
Founded2022
Founded2022
Employees238
Employees238
WOK Key Statistics
Market cap228.15
Market cap228.15
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume549.08K
Average volume549.08K
High today$2.50
High today$2.50
Low today$2.11
Low today$2.11
Open price$2.13
Open price$2.13
Volume924.10K
Volume924.10K
52 Week high$930,000.00
52 Week high$930,000.00
52 Week low$1.78
52 Week low$1.78
Stock Snapshot
WORK Medical Technology Group LTD Class A(WOK) stock is priced at $2.40, giving the company a market capitalization of 228.15.
As of 2026-08-16, WORK Medical Technology Group LTD Class A(WOK) stock has fluctuated between $2.11 and $2.50. The current price stands at $2.40, placing the stock +13.7% above today's low and -4.0% off the high.
WORK Medical Technology Group LTD Class A(WOK) shares are trading with a volume of 924.1K, against a daily average of 549.08K.
During the past year, WORK Medical Technology Group LTD Class A(WOK) stock moved between $1.78 at its lowest and $930,000.00 at its peak.
During the past year, WORK Medical Technology Group LTD Class A(WOK) stock moved between $1.78 at its lowest and $930,000.00 at its peak.
WOK News
TipRanks 1d
WORK Medical Technology Group Files H1 2026 Results Showing Rapid Asset Growth but Weaker Margins - TipRanks...
People also own
Based on the portfolios of people who own WOK. This list is generated using Robinhood data, and it’s not a recommendation.